TABLE 1.
Demographic data
| Subclinical Inflammation (n = 37) |
|||||
|---|---|---|---|---|---|
| B-TCMR (n = 24) | SC-TCMR (n = 13) | Total (n = 37) | NOMOA (n = 66) | P-value | |
| Age at transplant (y) | 12.6 ± 5.2 | 6.9 ± 6.3 | 10.6 ± 6.2 | 12.1 ± 5.2 | .17a |
| Sex (male/female) | 12/12 | 9/4 | 21/16 | 49/17 | .07 |
| Donor type (living [related or unrelated]/deceased) | 4/20 | 3/10 | 7/30 | 25/41 | .05 |
| Race (black/nonblack) | 14/10 | 4/9 | 18/19 | 28/38 | .54 |
| Cold ischemia time (h) | 17.1 ± 10.1 | 12.1 ± 9.8 | 15.3 ± 10.1 | 14.8 ± 9.2 | .85 |
| Transplant vintage (year) | 2.9 ± 1.7 | 2.8 ± 1.8 | 2.9 ± 1.7 | 3.4 ± 1.5 | .14 |
| Repeat kidney transplant (no., %) | 1 (4%) | 0 (0%) | 1 (3%) | 2 (3%) | 1.00 |
| Tacrolimus trough at 3 mo posttransplant (ng/mL) | 8.6 ± 2.3 | 8.1 ± 2.6 | 8.4 ± 2.4 | 8.8 ± 3.1 | .53 |
| Tacrolimus trough at 6 mo posttransplant (ng/mL) | 7.7 ± 3.0 | 7.0 ± 2.4 | 7.4 ± 2.8 | 7.3 ± 2.3 | .92 |
| HLA mismatches (no./10 total) | 7.4 ± 1.4 | 7.2 ± 2.1 | 7.3 ± 1.6 | 6.9 ± 2.3 | .30b |
| HLA-A (no.) | 1.4 ± 0.7 | 1.4 ± 0.7 | 1.4 ± 0.7 | 1.4 ± 0.7 | .74 |
| HLA-B (no.) | 1.7 ± 0.5 | 1.6 ± 0.5 | 1.7 ± 0.5 | 1.6 ± 0.6 | .52 |
| HLA-C (no.) | 1.4 ± 0.6 | 1.3 ± 0.8 | 1.4 ± 0.7 | 1.4 ± 0.6 | .87 |
| HLA-DR (no.) | 1.5 ± 0.5 | 1.6 ± 0.5 | 1.5 ± 0.5 | 1.4 ± 0.6 | .52 |
| HLA-DQ (no.) | 1.5 ± 0.5 | 1.4 ± 0.5 | 1.4 ± 0.5 | 1.2 ± 0.7 | .07 |
| DSA during year-1 posttransplant (no./assessed, %) | 3/18 (17%) | 1/10 (10%) | 4/28 (14%) | 5/51 (10%) | .55 |
| Class I only (no., %) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1.00 |
| Class II only (no., %) | 1 (6%) | 0 (0%) | 1 (4%) | 3 (6%) | .79 |
| Class I and II (no., %) | 2 (11%) | 1 (10%) | 3 (11%) | 2 (4%) | .35 |
| Nonadherence ≤6 mo posttransplant (no, %) | 4 (17%) | 4 (31%) | 8 (22%) | 8 (12%) | .20 |
| Subclinical inflammation at 3 mo (no., %) | 10 (42%) | 5 (38%) | 15 (41%) | N/A | — |
| Subclinical inflammation at 6 mo (no., %) | 14 (58%) | 8 (62%) | 22 (59%) | N/A | — |
| Treated surveillance findings (no., %) | 8 (33%) | 13 (100%) | 21 (57%) | N/A | — |
Comparisons were made between the combined subclinical inflammation (n = 37) and no major abnormalities (n = 66) groups using Student’s t-test, chi-square test, or Fisher’s exact test, as appropriate.
B-TCMR, borderline T cell–mediated rejection; DSA, donor-specific antibody; NOMOA, no major abnormalities; SC-TCMR, subclinical T cell–mediated rejection.
a
P-value represents comparison of mean age at transplant between subclinical inflammation and normal surveillance groups. The mean age at transplant was significantly different between B-TCMR and SC-TCMR subgroups at P < .01.
b
HLA mismatch data were available in 96 subjects.